The present findings provide preliminary experimental evidence for the potential use of this secreted FNDC5 derivative (sFNDC5) for the treatment of obesity and obesity-related metabolic disorders. Here, FNDC5 is linked to obesity due to melanocortin 4 receptor deficiency.